Triquetra Medicines Information

We are a passionate and obsessively patient- and Public Health-focused pharmaceutical R&D-based company identifying and developing drug product opportunities with high clinical or preclinical therapeutic validation in areas of high medical need. We have no declared Therapy Area or pharmaceutical modulator preference. Our specific expertise lies in the ability to reconfigure and bring to life drug product opportunities deemed unsuitable for the business models of branded products and generics. Branded products are dependent on IP supporting absolute market exclusivity and maximized pricing models, generics on copying existing products but not active, innovative drug development. Patients and Public Health must choose between expensive and innovative branded products or cheap(er) generics often representing the science of >20-30 years ago. Our approach still requires top-notch science but allows for faster, cheaper, and less risky drug development resulting in innovative but affordable products - in short, a niche between branded products and generics. Current activities focus on our exemplary signature product, TRQ001, for treating and diagnosing acute migraine and other primary headache forms. We aim to deliver a completely new, exceptionally effective, safe, and affordable prescription product with very low chemical and biological burden for our patients. Our next milestone is Phase II clinical trials in acute migraine patients.